New drug prices increased by 51% over three years, often exceeding value benchmarks, potentially costing the healthcare system $1.5 billion. Providers worry about medication stocking due to Part B ...
Transparency, prior authorization, PBM reform and PBM offered genomics testing are some the trends Formulary Watched tracked ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...
Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...
A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...
Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...
However, one significant problem has proven surprisingly durable: misdiagnosis of Type 1 diabetes (T1D). Estimates suggest ...
A new influenza strain could fuel a severe flu season while a surge in measles cases threatens U.S. elimination status, ...
The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...
Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...
Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback